Imaging paragangliomas using a new PET/CT method
Exendin PET/CT for Paragangliomas
This study is testing a new imaging method using a special tracer to see if it can help find and understand paragangliomas in patients who are about to have surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Radboud University Medical Center Academic / other |
| Locations | 1 site (Nijmegen) |
| Trial ID | NCT05418907 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the glucagon-like peptide 1 receptor (GLP-1R) as a novel target for molecular imaging of paragangliomas (PGLs). Investigators will use the tracer 68Ga-NODAGA-exendin 4 for positron emission tomography/computed tomography (PET/CT) imaging in patients with confirmed PGLs. The study will involve 10 patients who have undergone standard diagnostic imaging and are scheduled for surgery. The primary objective is to assess the feasibility of this new imaging technique for localizing and characterizing PGLs.
Who should consider this trial
Good fit: Ideal candidates are adults with a confirmed diagnosis of sympathetic paraganglioma and scheduled for surgery.
Not a fit: Patients with evidence of metastatic disease or other malignancies may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the accuracy of imaging for paragangliomas, leading to better surgical planning and outcomes.
How similar studies have performed: While existing imaging modalities have shown variable results, this approach using GLP-1R is novel and has not been extensively tested in this context.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Proven sympathetic PGL with a single tumor detected using standard diagnostic imaging * No evidence of metastatic disease * CT, SSTR PET/CT and 18F-FDG PET/CT performed (golden standard diagnostic imaging) * Scheduled for surgery * Able to sign informed consent Exclusion Criteria: * Breast feeding * Pregnancy or the wish to become pregnant within 1 month * Calculated creatinine clearance below 40ml/min * Evidence of other malignancy than PGL in conventional imaging (suspicious liver, bone and lung lesions) * Age \< 18 years * Not able to sign informed consent
Where this trial is running
Nijmegen
- Radboud University Medical Center — Nijmegen, Netherlands (Recruiting)
Study contacts
- Study coordinator: Marti Boss, PhD
- Email: marti.boss@radboudumc.nl
- Phone: +31243613813
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.